Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Tirapazamine (Win59075) 是抗癌剂,对实体瘤中的缺氧细胞具有选择性细胞毒性,促使 DNA 中的单链和双链断裂,碱基损伤和细胞死亡。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
10 mg | ¥ 220 | 现货 | ||
25 mg | ¥ 350 | 现货 | ||
50 mg | ¥ 547 | 现货 | ||
100 mg | ¥ 927 | 现货 | ||
200 mg | ¥ 1,530 | 现货 | ||
500 mg | ¥ 2,590 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 183 | 现货 |
产品描述 | Tirapazamine (Win59075) is a potent cytotoxic agent under hypoxic conditions, can induce apoptosis by inducing breaks in single and double-stranded DNA, as well as chromosomal breaks. The compound sensitizes cells to other ionizing radiation and other cytotoxic agents like cisplatin. |
体外活性 | Tirapazamine could downregulate HIF-1α expression by decreasing HIF-1α protein synthesis. The enhanced apoptosis induced by tirapazamine plus SN-38 (the active metabolite of irinotecan) was accompanied by increased mitochondrial depolarization and caspase pathway activation [1]. |
体内活性 | The increased the anticancer efficacy of tirapazamine combined with irinotecan was further validated in a human liver cancer Bel-7402 xenograft mouse model [1]. Rats were intraperitoneally injected six times once a week with tirapazamine in two doses, 5 (5TP) and 10 mg/kg (10TP), while doxorubicin was administered in dose 1.8 mg/kg (DOX). Subsequent two groups received both drugs simultaneously (5TP+DOX and 10TP+DOX). Tirapazamine reduced heart lipid peroxidation and normalized RyR2 protein level altered by doxorubicin [2]. |
别名 | Tirazone, Win59075, SR4233, 替拉扎明, SR259075 |
分子量 | 178.15 |
分子式 | C7H6N4O2 |
CAS No. | 27314-97-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (280.66 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 5.6132 mL | 28.0662 mL | 56.1325 mL | 140.3312 mL |
5 mM | 1.1226 mL | 5.6132 mL | 11.2265 mL | 28.0662 mL | |
10 mM | 0.5613 mL | 2.8066 mL | 5.6132 mL | 14.0331 mL | |
20 mM | 0.2807 mL | 1.4033 mL | 2.8066 mL | 7.0166 mL | |
50 mM | 0.1123 mL | 0.5613 mL | 1.1226 mL | 2.8066 mL | |
100 mM | 0.0561 mL | 0.2807 mL | 0.5613 mL | 1.4033 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Tirapazamine 27314-97-2 Others inhibit SML-0552 Tirazone SML0552 SML 0552 SR-4233 Bioreductive Agent Win59075 Win-59075 Inhibitor Win 59075 SR 259075 SR4233 SR-259075 Anticancer Agent 替拉扎明 SR 4233 SR259075 inhibitor